Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908118 | 0.85 | L3MBTL1 (0.49) | L3MBTL1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL829668 | 0.84 | TDP1 (0.46) | L3MBTL1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL830138 | 0.82 | L3MBTL1 (0.41) | L3MBTL1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL863151 | 0.81 | GAA (0.45) | L3MBTL1MAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL9964595 | 0.81 | L3MBTL1 (0.37) | L3MBTL1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL7033025 | 0.80 | LMNA (0.59) | L3MBTL1MAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11268274 | 0.80 | GAA (0.47) | L3MBTL1MAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL830970 | 0.80 | PTGS2 (0.52) | L3MBTL1MAPTALDH1A1GAALMNA | |
| SCHEMBL8708325 | 0.79 | HDAC1 (0.56) | L3MBTL1MAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL863376 | 0.77 | L3MBTL1 (0.47) | L3MBTL1MAPTALDH1A1GAAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | BEZWADA BIOMEDICAL, LLC (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | HAO2, AOC2, AOC1 | L3MBTL1 540/4885MAPT 2702/4885ALDH1A1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.